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a b s t r a c t 
Burkholderia pseudomallei causes melioidosis, a potentially lethal disease that can establish both chronic 
and acute infections in humans. It is inherently recalcitrant to many antibiotics, there is a paucity of 
effective treatment options and there is no vaccine. In the present study, the efficacies of selected 
aminocoumarin compounds, DNA gyrase inhibitors that were discovered in the 1950s but are not in clin- 
ical use for the treatment of melioidosis were investigated. Clorobiocin and coumermycin were shown 
to be particularly effective in treating B. pseudomallei infection in vivo . A novel formulation with dl - 
tryptophan or l -tyrosine was shown to further enhance aminocoumarin potency in vivo . It was demon- 
strated that coumermycin has superior pharmacokinetic properties compared with novobiocin, and the 
coumermycin in l -tyrosine formulation can be used as an effective treatment for acute respiratory me- 
lioidosis in a murine model. Repurposing of existing approved antibiotics offers new resources in a chal- 
lenging era of drug development and antimicrobial resistance. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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0. Introduction 
Burkholderia pseudomallei , a Gram-negative, soil-dwelling bac-
erium, is the causative agent of the potentially fatal disease, me-
ioidosis. Reports of B. pseudomallei being isolated from soil are
ow commonplace in subtropical climates, including Southeast
sia, Africa and South America, leading to concerns that the in-
idence of melioidosis will increase in the future [ 1 , 2 ]. 
Burkholderia pseudomallei can infect humans via two main
outes of entry: (i) inhalation of contaminated particles; and (ii)
ound site infection. It can then establish itself as either a chronic
nfection, potentially lasting for many years [3] , or as an acute ill-
ess owing to bacteraemia. It is also able to disseminate in the
ost via the circulatory and lymphatic systems. Melioidosis is dif-
cult to treat because B. pseudomallei has inherent resistance to
any commonly used antibiotics, notably β-lactam compounds,
uoroquinolones and ciprofloxacin [4] . There is currently no ef-
ective vaccine that is safe for use in humans and it is estimated
hat melioidosis was responsible for more than 89 0 0 0 deaths in
016 [5] . Treatment of the acute infection involves intravenous
dministration of the frontline antibiotic ceftazidime for up to
 weeks, followed by secondary treatment with oral trimetho-∗ Corresponding author. 
E-mail address: Brendan.wren@lshtm.ac.uk (B.W. Wren). 
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924-8579/© 2020 The Authors. Published by Elsevier B.V. This is an open access article urim/sulfamethoxazole (co-trimoxazole) for a further 3 months to
radicate persistent intracellular bacteria [6] . 
Antibiotic resistance in B. pseudomallei is mediated by a
ormidable array of factors encoded by a large genome spread
ver two chromosomes. The thick polysaccharide capsule can re-
ist complement, aminoglycosides and antimicrobial peptide stress
6] ; efflux pumps can reduce susceptibility to chloramphenicol and
acrolides; and overproduction of β-lactamases and deletion of
enicillin-binding proteins can confer resistance to ceftazidime [6] .
 recent study of the related species Burkholderia cepacia found
hat only around one-quarter of > 2500 isolates from cystic fibro-
is patients were susceptible to any treatment whatsoever, despite
esting 23 different antibiotic combinations [7] . 
Novel, repurposed or reformulated antibiotics are required to
rovide more effective treatment options for Burkholderia infec-
ions. The current state of drug development is that no new classes
f antibiotic effective against Gram-negative bacteria have been ap-
roved since 1962 [8] . Compounding this, many pharmaceutical
ompanies are withdrawing from antibiotic development, in part
ue to unfavourable economic incentives [9] . In light of this, mak-
ng better use of antibiotics that are already in clinical use repre-
ents a possible cost-effective and expeditious solution. 
Aminocoumarins, which include novobiocin, coumermycin and 
lorobiocin, are a class of antibiotics that target the ATPase activity
f the GyrB subunit of DNA gyrase and the ParE subunit of topoiso-
erase IV, disrupting DNA replication and transcription. They bindnder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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t  gyrase with greater affinity than quinolones, which target the GyrA
subunit, and they additionally prevent ATP binding [10] . 
Novobiocin, also known as albamycin, was discovered in the
1950s derived from Streptomyces niveus and was shown to be ac-
tive against B. pseudomallei in vitro, particularly in synergy with
tetracycline [11] . Despite this early promise, there is a paucity of
data on the use of aminocoumarins to treat melioidosis. Com-
monly cited reasons include their poor solubility as well as con-
cerns over the potential emergence of drug resistance [12] . Efforts
to improve the pharmacokinetics of these compounds have some-
times been accompanied by a loss of affinity for the bacterial target
site, and such programmes have since been discontinued (reviewed
by Bisacchi and Manchester [13] ). 
Given the high mortality associated with acute melioidosis
( > 70% without appropriate antibiotic treatment [5] ), the difficul-
ties with existing treatment options and the unrealised potential
shown by aminocoumarins, we sought to revisit this class of com-
pounds as a potential therapeutic agent against B. pseudomallei in-
fection using two different in vivo models. In the current study,
the efficacies of commercially available aminocoumarins were as-
sessed and the Galleria mellonella (wax moth) larvae model was
used to screen for effective formulations that could improve in vivo
activity in a murine model. These findings were applied to demon-
strate that coumermycin in equimolar solution with l -tyrosine sig-
nificantly improves survival in a murine infection model of acute
melioidosis. 
2. Methods 
2.1. Galleria mellonella infection assay 
Different formulations were investigated to improve the
bioavailability and efficacy of poorly soluble compounds, using
novobiocin as a representative aminocoumarin. The compounds
clorobiocin, coumermycin (A1) and novobiocin (all from Sigma-
ldrich, Gillingham, UK) were solubilised in dimethyl sulfoxide
(DMSO) carrier at a stock concentration of 10 mg/mL. For injec-
tion into G. mellonella larvae, the stock solution was diluted in
sterile saline to a final concentration of 1 mg/mL. Saline solutions
were prepared with either sodium alginate, povidone or methylcel-
lulose at different concentrations ranging from 0–1% [w/v sterile
phosphate-buffered saline (PBS)]. Alternatively, and also in com-
bination, the amino acids l -tyrosine, dl -tryptophan or casamino
acids (Sigma-Aldrich) were added at various molar ratios relative
to the antibiotic. Casamino acids contain all amino acids except
tryptophan. For infection, five Galleria larvae per group of match-
ing size were injected with ~150 CFU of B. pseudomallei in a 10
μL volume in the uppermost right footpad. Galleria larvae were
then incubated at 37 °C for 1 h. At this time, Galleria were injected
in the uppermost left footpad with 10 μL of antibiotic solution
or saline control. Galleria larvae were then incubated for 24 h at
37 °C. To enumerate the bacterial load, haemolymph was drained
into a sterile 1.5 mL Eppendorf tube. Then, 10 μL of haemolymph
was serially diluted in sterile PBS with 0.1% Tween 80 and was
plated onto Luria–Bertani (LB) agar for CFU enumeration of ex vivo
isolated B. pseudomallei . 
2.2. Murine infection 
Female BALB/c mice (Charles Rivers Laboratories International,
Inc., Margate, UK) aged 6–8 weeks were used. Mice were housed
under specific pathogen-free (SPF) conditions with free access to
food and water. Animal work was performed in accordance with
the Animals (Scientific Procedures) Act of 1986 and the local Ethi-
cal Review Committee, under animal biohazard Containment Level
3 conditions. All units were infected intranasally with a total of00 CFU of B. pseudomallei K96243 by pipetting 25 μL into each
ostril. Treatment began at 6 h post-infection, followed by treat-
ent once every 24 h for 4 consecutive days thereafter. Treatment
omprised either sterile saline (negative control), 1200 mg/kg cef-
azidime (intraperitoneal), 30 mg/kg coumermycin (subcutaneous)
r 30 mg/kg coumermycin in solution with equimolar l -tyrosine
subcutaneous). In all cases, mice were checked at least daily for
igns of illness and, if determined to have reached the humane
ndpoint specified in the Project Licence, were euthanised. The ex-
eriment was concluded at 30 days post-infection. 
.3. Pharmacokinetics 
Pharmacokinetic studies were performed by Domainex (Saffron
alden, UK). Three BALB/c units per group were injected intraperi-
oneally with 15 mg/kg novobiocin or coumermycin ± 0.7 mg/mL
l -tryptophan, formulated in 5% DMSO in 95% Kleptose R © (8% w/v
n PBS). Animals were housed in pre-assigned cages until sampling.
ppropriate samples were taken at the defined time points and
ere stored immediately at –20 °C. Protein was precipitated with
cetonitrile and then ultra-high performance liquid chromatogra-
hy time-of-flight mass spectrometry (UHPLC-TOF/MS) using elec-
rospray ionisation was used to quantify the compound concentra-
ion in plasma. 
.4. Statistical analysis 
All data analysis was performed using GraphPad Prism 8.1.2
GraphPad Software Inc., La Jolla, CA, USA). For comparison of the
ffect of different treatment conditions on the bacterial load in
alleria haemolymph, one-way analysis of variance (ANOVA) was
erformed with Dunnett’s multiple comparisons test compared
ith the untreated condition or unformulated novobiocin as indi-
ated. For murine survival studies, log-rank (Mantel–Cox) test was
erformed for each treatment condition versus the saline control
roup. 
. Results and discussion 
.1. The aminocoumarin formulation significantly alters its in vivo 
ctivity 
Historically, only limited assessment of aminocoumarin activity
gainst B. pseudomallei infection in vivo has been performed. In the
urrent study, two different in vivo models were chosen to assess
he efficacy of a group of aminocoumarin compounds, initially us-
ng G. mellonella larvae to screen the effect of different drug for-
ulations before proceeding to an experimental model of acute
elioidosis using a murine infection model. Use of G. mellonella
arvae is an increasingly popular method for host–pathogen viru-
ence studies as well as for screening drug efficacy and safety. They
epresent a more complex model than any single cell line since
hey possess multiple different cell types, tissue differentiation and
erum factors including host defence peptides and complement-
ike proteins [ 14 , 15 ]. They are particularly valuable not as a com-
lete replacement of murine studies but in reducing the size of
hose experiments by defining experimental conditions and testing
ypotheses a priori. 
To assess compound activity in vivo, G. mellonella larvae were
reated 1 h after infection with ~150 CFU of B. pseudomallei . Novo-
iocin, whilst highly active in vitro [minimum inhibitory concen-
ration (MIC) < 10 μg/mL], showed no significant killing activity in
ivo, whereas clorobiocin and coumermycin significantly reduced
he bacterial load ( Fig. 1 A). Clorobiocin is reportedly a more po-
ent inhibitor of gyrase and topoisomerase IV than novobiocin, al-
hough it is difficult to source commercially and is not in clinical
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Fig. 1. The novobiocin formulation modifies in vivo potency in Galleria mellonella larvae . Galleria larvae ( n = 5 per group) were infected with Burkholderia pseudomallei 
K96243 (110–178 CFU) for 1 h at 37 °C and were then treated with different aminocoumarins (10 μL of 1 mg/mL stock solution) or novobiocin in different formulations as 
indicated. One-way analysis of variance (ANOVA) was performed with Dunnett’s multiple comparisons test versus (A,B) untreated larvae or (C,D) novobiocin formulation in 
phosphate-buffered saline (PBS). Representative figures from at least three independent biological replicates are shown. Error bars represent the standard deviation from the 
mean. ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0 0 01; NS , not significant. 
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l  se [16] . Coumermycin has a structure similar to a dimer of novo-
iocin and, like clorobiocin, proved to be more potent than novo-
iocin in vivo at the same dose. Both Clorobiocin and coumermycin
re reported to have improved membrane permeability compared
ith novobiocin [13] , which may explain these findings. With
hese two aminocoumarins, all Galleria larvae survived and showed
o signs of disease after 24 h of infection, whereas no larvae
reated with novobiocin survived longer than 24 h post-infection.
aemolymph from clorobiocin- and coumermycin-treated larvae
as also clear from significant amounts of B. pseudomallei , and in
ome cases (100% and 60%, respectively) was sterile of any bacte-
ia. 
Use of certain amino acids as co-amorphous partners has been
eported to increase the solubility of poorly water-soluble drugs
 17 , 18 ]. We therefore investigated the effect of addition of either l -
yrosine, dl -tryptophan or casamino acids at various molar ratios
n the in vivo efficacy of novobiocin ( Fig. 1 A,B). Tryptophan and ty-
osine, but not casamino acids, improved the activity of novobiocin
t equimolar ratios, showing reduced bacterial burden in Galleria
arvae. Since casamino acids, which contain a mixture of amino
cids minus tryptophan, were not effective at enhancing activity,
e suggest that a unique property of tyrosine and tryptophan—
otentially their non-polar aromatic carbon ring—is responsible for
he improved novobiocin activity. The fact that the molar ratio ofmino acid to novobiocin influenced synergy suggests that specific
toichiometry is important for optimal interaction. 
To investigate the synergy with amino acid formulation fur-
her, novobiocin was chemically conjugated to a fluorescent re-
orter compound (Supplementary methods; Supplementary Fig. 
1A) and its tissue distribution was imaged in histological sam-
les of treated, non-infected Galleria larvae (Supplementary Fig.
1C) . No significant effect on drug accumulation in adipose or
aemolymphatic tissue was observed. The mechanism of in vivo
ynergy between dl -tryptophan, l -tyrosine and aminocoumarins
emains to be established. 
Novobiocin exists in solution as an equilibrium between two
orms, its less bioactive crystalline form and its more bioactive
morphous form. Unlike the crystalline form, the amorphous form
s readily absorbed in vivo via the gastrointestinal tract leading
o high blood concentrations [19] . Gelling agents have been pre-
iously described to suppress crystallisation of similar compounds,
hus in the current study different formulations of povidone and
odium alginate with novobiocin were tested. Whilst povidone sig-
ificantly increased bacterial CFU during Galleria infection, sodium
lginate formulations appeared to reduce the bacterial burden, al-
hough this was not statistically significant ( Fig. 1 C,D). Gelling
gents can be problematic due to the associated changes in so-
ution viscosity. Techniques such as nanosuspension and prodrug
4 S.J. Willcocks, F. Cia and A.F. Francisco et al. / International Journal of Antimicrobial Agents 56 (2020) 106002 
Table 1 
Summary of mean pharmacokinetic parameters. 
Parameter Coumermycin Novobiocin 
Alone + dl -tryptophan Alone + dl -tryptophan 
t 1/2 (h) 6 6 3 3 
T max (h) 2 2 1 1 
C max (nM) 102 767 103 297 10 739 10 739 
AUC last (h •nM) 957 128 909 773 33 198 33 198 
AUC all (h •nM) 957 128 909 773 33 198 33 198 
AUC inf (h •nM) 1 016 517 963 025 33 240 33 240 
t 1/2 , elimination half-life; T max , time to maximum concentration; C max , maximum concentration; AUC, 
area under the concentration–time curve (AUC last , AUC from 0 h to last measurable concentration; 
AUC all , AUC for all values; AUC inf , AUC from 0 h to infinity). 
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Fig. 2. Pharmacokinetics of novobiocin and coumermycin. Female BALB/c mice 
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B  formulation with phosphate esters have been explored by phar-
maceutical companies with mixed success. Alternative methods
such as polymersome encapsulation [ 20 , 21 ] or microgel formula-
tion may enhance novobiocin efficacy in vivo and remain to be
tested. 
3.2. Coumermycin shows improved pharmacokinetics in vivo 
compared with novobiocin 
The G. mellonella data suggested that while both compounds are
effective against B. pseudomallei in vitro, coumermycin retains ac-
tivity in vivo, in contrast to novobiocin. We sought to characterise
the pharmacokinetic profile of both compounds in a murine model
by injection of either compound into the intraperitoneal cavity
and quantification of its absorption into peripheral blood plasma
( Fig. 2 ). Whilst some mild toxicity including skin rash and nausea
has been reported with the use of novobiocin, other reports sug-
gest that it is in fact generally well tolerated and that impurities
in the formulation may instead be responsible for such side effects
[10] . In the present study, no toxicity was observed at the dosage
of coumermycin used in the murine experiments. 
It was found that while novobiocin reached a peak concen-
tration of 10 739 nM, coumermycin peaked at 102 767 nM and
also had a significantly longer half-life in plasma (5.9 h vs. 2.8
h) ( Table 1 ). The half-life values are similar to those reported by
others [ 10 , 22 ], whilst the plasma concentrations for coumermycin
are substantially higher than in studies that used a subcutaneous
rather than intraperitoneal injection route [23] , even accounting
for differences in treatment dose. The relatively low plasma con-
centration of novobiocin may explain its loss of activity in vivo
since the unbound (free) drug available is likely to be less than the
threshold required to inhibit topoisomerase and gyrase [13] . Inter-
estingly, addition of dl -tryptophan, which improved antibiotic ac-
tivity in Galleria , did not influence the pharmacokinetics for either
drug in the murine model. 
3.3. Treatment with coumermycin protects against acute melioidosis 
in a murine model 
Since coumermycin was highly active in the Galleria screen and
showed enhanced pharmacokinetics over novobiocin, this com-
pound was selected as the test aminocoumarin for treatment of
melioidosis in an acute murine model of infection [24] . Novo-
biocin has previously shown potential in the treatment of sepsis
caused by Streptococcus pneumoniae [10] . Since formulation with l -
tyrosine enhanced the in vivo activity of novobiocin, we reasoned
that it may similarly enhance the potency of coumermycin. Cef-
tazidime, the currently recommended antibiotic for treating me-
lioidosis, was used as a comparative control. 
All treatment groups had a significantly improved survival rate
until the end of the experiment compared with the saline-treated
control group ( Fig. 3 A). In agreement with the Galleria data, thefficacy of coumermycin was enhanced by formulation with a 1:1
olar ratio l -tyrosine, with 100% survival at 30 days post-infection
ompared with 60% survival with ceftazidime and 40% survival
ith coumermycin alone. In general, the coumermycin treatment
roups scored better for clinical symptoms of disease than the cef-
azidime group and recovered a greater percentage of body weight
 Fig. 3 B). 
It is notable that successful treatment with coumermycin was
chieved with one-fortieth the dose of ceftazidime. Of the surviv-
ng units at the termination of the experiment, homogenised lung
nd spleen tissue were examined for pathology and bacterial bur-
en. All surviving ceftazidime-treated mice showed splenomegaly
ontaining > 1 × 10 7 CFU bacteria, and two of three also had
. pseudomallei bacilli present in their lungs. By comparison, 40%
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 f surviving units from the coumermycin plus l -tyrosine group
emonstrated splenomegaly, with no bacteria in their lung. At the
nd of the experiment, 40% of units from the coumermycin treat-
ent group and 60% from the coumermycin plus l -tyrosine group
howed complete organ sterility. 
The only previous report of coumermycin being tested against
. pseudomallei in vivo was from a 1970 study that used pig mucin
o deplete host immunity [25] . Six doses of coumermycin over 72 h
howed significant activity against multiple strains of B. pseudoma-
lei using an intraperitoneal infection model. In the present work, a
ode of infection via the aerosol route was simulated, which more
losely reflects the clinical situation in endemic countries. 
Antimicrobial resistance among many pathogens is a legiti-
ate concern. Success in this regard has been reported by util-
sing novobiocin combined with rifampicin in a dual-therapy ap-
roach that mitigates drug resistance [10] . Novel related an-
ibiotics such as kibdelomycin are also effective against strains
f bacteria that are otherwise resistant to aminocoumarins or
uinolones [26] . There is also promise in the rational design of
ovel aminocoumarins through metabolic engineering of the pro-
ucer strains of Streptomyces sp. [27] . 
. Conclusions 
Taken together, these data suggest that aminocoumarins de-
erve renewed attention for their potential to treat melioidosis
nd potentially other diseases. Some doubts over their use have
ocussed on their pharmacokinetic properties, potential side ef-ects and the potential for the development of resistance. In the
resent work, we demonstrate innovative methods for improving
heir bioactive potential. Given the lack of development of new
ntibiotics, we cannot afford to ignore the potential benefits that
minocoumarins may have to offer. 
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